A number of different definitions for the metabolic syndrome have been proposed ([@B1]--[@B4]), with the cut points for each component and their combinations derived primarily from expert opinion. The lack of an empirically derived definition hinders evaluation of opposing arguments concerning the clinical utility of the metabolic syndrome.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Data from the prospective Framingham Offspring, Atherosclerosis Risk in Communities (ARIC), and Cardiovascular Health studies were pooled as previously described ([@B5]). Informed consent and appropriate institutional review board approval were obtained for each study. For the Framingham Offspring Study, the fourth examination was used as the baseline visit because it was the first time point at which waist circumference was measured. Individuals reporting a history of cardiovascular disease (CVD) at baseline, fasting \<8 h, aged \<45 years, or underweight (BMI \<18.5 kg/m^2^) were excluded.

CVD outcomes included probable and definite fatal and nonfatal coronary heart disease (CHD) and stroke for all studies ([@B6]--[@B9]). CHD was defined as myocardial infarction, silent myocardial infarction, or CHD death, and stroke included both hemorrhagic and ischemic subtypes.

Participants were classified as having metabolic syndrome according to three existing definitions as follows. ATP III definition, three or more of the following criteria: *1*) waist circumference \>102 cm in men and \>88 cm in women, *2*) triglycerides ≥1.7 mmol/L, *3*) HDL cholesterol \<1.0 mmol/L (men) or \<1.3 mmol/L (women), *4*) blood pressure ≥130/85 mmHg or antihypertensive medication use, and *5*) glucose ≥5.6 mmol/L or antidiabetes medication use (or physician diagnosis for ARIC). International Diabetes Federation (IDF) definition, abdominal adiposity (waist circumference ≥94 cm \[men\] or ≥80 cm \[women\]) and two or more risk factors from numbers 2 through 5 above. Harmonized definition, identical to the ATP III definition except that IDF waist circumference cut points were used. Information on medications for raising HDL cholesterol, needed for the Harmonized definition, were not ascertained but were expected to be infrequent given that baseline exams occurred prior to 1992.

The cut point for each component of the metabolic syndrome and the resulting number of such cut points that maximized the sum of sensitivity and specificity for incident CVD events were calculated. The relative integrated discrimination improvement (RIDI) was then calculated ([@B10]), with values greater than zero indicating better overall discrimination for empirically derived versus existing definitions. Cox proportional hazards regression was used to calculate hazard ratios (HRs) for incident CVD events associated with each metabolic syndrome definition, adjusting for age, sex, race, education level, smoking status, alcohol intake, and study (ARIC, Cardiovascular Health Study \[CHS\], and Framingham Offspring).

RESULTS {#s6}
=======

Across the three studies (*n* = 20,581), 1,783 incident CVD events occurred over 9 years of follow-up. In the overall sample, the optimal systolic and diastolic blood pressure and triglyceride cut points were lower than those in existing definitions, whereas the glucose cut point was identical ([Table 1](#T1){ref-type="table"}). Within demographic subgroups, the optimal cut point varied by component and subgroup.

###### 

Empirically derived cut points and associated discrimination performance statistics for metabolic syndrome components by demographic subgroups

                                                                                  Overall   White men (aged \<65 years)   White women (aged \<65 years)   Black men (aged \<65 years)   Black women (aged \<65 years)   White men (aged ≥65 years)   White women (aged ≥65 years)   Black men (aged ≥65 years)   Black women (aged ≥65 years)
  ------------------------------------------------------------------------------- --------- ----------------------------- ------------------------------- ----------------------------- ------------------------------- ---------------------------- ------------------------------ ---------------------------- ------------------------------
  *N*                                                                             20,581    5,720                         6,577                           1,332                         2,198                           1,667                        2,443                          238                          406
  Systolic blood pressure (excluding those taking antihypertensive medication)                                                                                                                                                                                                                                   
    *N*                                                                           14,543    4,556                         5,022                           889                           1,197                           1,064                        1,526                          133                          156
   Optimal cut point (mmHg)                                                       125       120                           120                             125                           130                             130                          135                            140                          140
   Sensitivity                                                                    0.62      0.59                          0.56                            0.72                          0.62                            0.69                         0.56                           0.48                         0.60
   Specificity                                                                    0.64      0.57                          0.64                            0.56                          0.71                            0.51                         0.62                           0.67                         0.69
  Diastolic blood pressure (excluding those taking antihypertensive medication)                                                                                                                                                                                                                                  
    *N*                                                                           14,543    4,556                         5,022                           889                           1,197                           1,064                        1,526                          133                          156
   Optimal cut point (mmHg)                                                       75        75                            70                              80                            75                              75                           70                             75                           75
   Sensitivity                                                                    0.47      0.54                          0.60                            0.62                          0.55                            0.43                         0.46                           0.57                         0.48
   Specificity                                                                    0.62      0.56                          0.52                            0.55                          0.51                            0.65                         0.57                           0.50                         0.62
  Glucose (excluding patients with diabetes)                                                                                                                                                                                                                                                                     
  * N*                                                                            18,479    5,254                         6,129                           1,151                         1,840                           1,410                        2,193                          186                          316
   Optimal cut point (mmol/L)                                                     5.6       5.6                           5.3                             5.6                           5.6                             5.6                          5.3                            5.6                          5.3
   Sensitivity                                                                    0.45      0.51                          0.56                            0.44                          0.46                            0.52                         0.62                           0.46                         0.51
   Specificity                                                                    0.63      0.57                          0.53                            0.56                          0.60                            0.53                         0.43                           0.58                         0.37
  Triglycerides (excluding those on cholesterol-lowering medication)                                                                                                                                                                                                                                             
  * N*                                                                            19,939    5,541                         6,373                           1,320                         2,161                           1,606                        2,330                          229                          379
   Optimal cut point (mmol/L)                                                     1.4       1.4                           1.4                             1.4                           1.4                             1.4                          1.4                            1.4                          1.4
   Sensitivity                                                                    0.50      0.59                          0.59                            0.38                          0.39                            0.51                         0.50                           0.28                         0.31
   Specificity                                                                    0.61      0.54                          0.65                            0.68                          0.72                            0.56                         0.53                           0.69                         0.66
  HDL cholesterol                                                                                                                                                                                                                                                                                                
   Optimal cut point (mmol/L)                                                     1.3       1.0                           1.4                             1.2                           1.4                             1.2                          1.4                            1.3                          1.6
   Sensitivity                                                                    0.58      0.57                          0.73                            0.48                          0.64                            0.51                         0.47                           0.40                         0.55
   Specificity                                                                    0.51      0.56                          0.51                            0.58                          0.52                            0.55                         0.58                           0.50                         0.49
  Waist circumference                                                                                                                                                                                                                                                                                            
   Optimal cut point (cm)                                                         96        98                            96                              96                            98                              98                           92                             96                           100
   Sensitivity                                                                    0.55      0.59                          0.53                            0.56                          0.62                            0.49                         0.46                           0.49                         0.54
   Specificity                                                                    0.55      0.51                          0.68                            0.53                          0.51                            0.55                         0.59                           0.42                         0.58

The presence of ≥3 components at levels above the optimal cut point (below the optimal cutpoint for HDL cholesterol), identified in [Table 1](#T1){ref-type="table"}, provided the highest sum of sensitivity and specificity, and two empirically derived metabolic syndrome definitions were created: *1*) three or more components using cut points derived in the full sample (uniform cut point definition) and *2*) three or more components using demographic subgroup-specific cut points.

More people were categorized as having metabolic syndrome using the empirically derived definitions (48.3% for uniform cut points and 51.0% for subgroup-specific cut points) compared with the ATP III (38.4%), IDF (35.6%), or Harmonized (46.0%) definitions. The empirically derived definitions, using uniform and subgroup-specific cut points, had higher sensitivity but lower specificity (0.65/0.53 and 0.67/0.50, respectively) versus the ATP III (0.53/0.63), IDF (0.51/0.66), or Harmonized (0.64/0.56) definitions. The empirically derived definition with uniform cut points provided little improvement over the ATP III (RIDI 5% \[95% CI −6 to 18\]), IDF (2% \[−9 to 14\]), or Harmonized (−0.2% \[−11 to 11\]) definitions. Results were markedly similar when subgroup-specific cut points were used.

All metabolic syndrome definitions were associated with an increased HR for incident CVD in multivariable-adjusted analyses (1.7 \[95% CI 1.6--1.9\], 1.8 \[1.6--2.0\], and 1.9 \[1.7--2.0\] for ATP III, IDF, and Harmonized, respectively, and 1.7 \[1.6--1.9\] and 1.8 \[1.6--1.9\] for the empirically derived uniform and subgroup-specific cut point definitions, respectively). Results were similar among individuals without hypertension or diabetes or when the HRs were adjusted for antihypertensive and lipid-lowering medication use. A fivefold cross-validation study resulted in identical cut points and similar performance characteristics.

CONCLUSIONS {#s7}
===========

The data-derived definitions of the metabolic syndrome resulting from maximization of the sum of sensitivity and specificity for CVD events resulted in little improvement in discrimination compared with existing definitions. Also, the HRs for CVD associated with each metabolic syndrome definition were similar.

The empirical derivation resulted in cut points similar to those based on expert opinion used in existing metabolic syndrome definitions. The exception was the empirically derived triglyceride cut point (1.4 mmol/L), which was substantially lower than that used in existing definitions (1.7 mmol/L). The lower triglyceride cut point resulted in a higher prevalence of the metabolic syndrome but no overall improvement in discrimination or meaningful difference in the HR for CVD.

For the ATP III, IDF, and Harmonized definitions, sex-specific cut points are applied for HDL cholesterol and waist circumference criteria. In the current study, subgroup-specific cut points resulted in higher sensitivity in some groups at the expense of lower specificity. In other subgroups, specificity was higher but sensitivity lower. Given this, the lack of improvement in discrimination when using subgroup-specific cut points, and the similarity of HRs between the empirically derived uniform cut point definition and existing definitions, which use sex-specific cut points, these data suggest that uniform cut points in all subgroups may be sufficient for discrimination and assessing associations. This results in a simplified clinical application.

Although measurement protocols were not identical across the three studies, findings were similar within each study (data not shown). The strength of this study comes from the use of a large sample with over 1,700 incident CVD events.

Although the ATP III, IDF, and Harmonized definition cut points were not empirically derived, the improvements in CVD risk prediction seen with empirically derived cut points were small, suggesting that the existing metabolic syndrome definitions will be sufficient for use in clinical practice and research studies should the metabolic syndrome debate conclude in a recommendation for its continued use.
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